[ARQL] ArQule, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.29 Change: 0.03 (2.38%)
Ext. hours: Change: 0 (0%)

chart ARQL

Refresh chart

Strongest Trends Summary For ARQL

ARQL is in the long-term up 668% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company?s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research

Fundamental Ratios
Shares Outstanding EPS-0.36 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4% Sales Growth - Q/Q-7.63% P/E-3.11
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.6% ROE-56.49% ROI
Current Ratio3.3 Quick Ratio Long Term Debt/Equity Debt Ratio0.45
Gross Margin Operating Margin-191.68% Net Profit Margin-183.06% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities15.23 M Cash From Operating Activities-7.55 M Gross Profit
Net Profit-4.55 M Operating Profit-4.82 M Total Assets55.32 M Total Current Assets55.08 M
Total Current Liabilities16.7 M Total Debt Total Liabilities18.5 M Total Revenue2.79 M
Technical Data
High 52 week7.03 Low 52 week2.26 Last close6.78 Last change-3.56%
RSI59.42 Average true range0.4 Beta1.25 Volume304.8 K
Simple moving average 20 days7.21% Simple moving average 50 days20.09% Simple moving average 200 days47.28%
Performance Data
Performance Week5.61% Performance Month6.94% Performance Quart98.83% Performance Half84.74%
Performance Year98.83% Performance Year-to-date144.77% Volatility daily3.84% Volatility weekly8.58%
Volatility monthly17.58% Volatility yearly60.9% Relative Volume733.06% Average Volume1.57 M
New High New Low

News

2019-11-13 07:00:00 | ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019

2019-11-06 09:05:00 | ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

2019-10-30 08:25:12 | ArQule ARQL Reports Q3 Loss, Lags Revenue Estimates

2019-10-30 07:00:00 | ArQule Reports Third Quarter 2019 Financial Results

2019-10-29 16:01:00 | ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2019-10-28 17:15:45 | Hedge Funds Have Never Been This Bullish On ArQule, Inc. ARQL

2019-10-21 07:00:00 | ArQule Announces Preclinical Data Demonstrating Potential of Miransertib ARQ 092 to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting

2019-10-16 07:00:00 | ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2019-10-16 07:00:00 | ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019

2019-10-15 09:00:01 | All You Need to Know About ArQule ARQL Rating Upgrade to Buy

2019-10-08 08:47:12 | Health Check: How Prudently Does ArQule NASDAQ:ARQL Use Debt?

2019-10-08 07:00:00 |  ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics ASHG Annual Meeting

2019-10-03 10:56:02 | ArQule ARQL in Focus: Stock Moves 6.2% Higher

2019-10-02 07:00:00 | ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum

2019-09-26 07:00:00 | ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019

2019-09-17 07:00:00 | ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019

2019-08-30 14:39:07 | ArQule: Buy the Dip?

2019-08-28 07:00:00 | ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019

2019-08-09 11:07:05 | What Kind Of Shareholders Own ArQule, Inc. NASDAQ:ARQL?

2019-08-07 23:23:42 | Arqule Inc ARQL Q2 2019 Earnings Call Transcript

2019-08-07 19:17:08 | Edited Transcript of ARQL earnings conference call or presentation 7-Aug-19 1:00pm GMT

2019-08-07 08:45:12 | ArQule ARQL Reports Q2 Loss, Misses Revenue Estimates

2019-08-07 07:00:00 | ArQule Reports Second Quarter 2019 Financial Results

2019-08-06 14:18:30 | Arqule's Earnings Preview

2019-08-06 12:00:04 | ArQule ARQL to Post Q2 Earnings: What's in the Cards?

2019-08-05 07:00:00 | ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019

2019-07-31 10:36:02 | Analysts Estimate ArQule ARQL to Report a Decline in Earnings: What to Look Out for

2019-07-24 09:00:01 | What Makes ArQule ARQL a New Buy Stock

2019-07-24 07:00:00 | ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019

2019-07-12 07:15:00 | 5 Best Biotech Stocks of 2019 So Far

2019-07-08 13:58:00 | Here's Why ArQule Jumped 53.1% in June

2019-06-27 13:09:00 | ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

2019-06-26 08:54:12 | Do Options Traders Know Something About ArQule ARQL Stock We Don't?

2019-06-25 15:16:00 | Here's the Surprising Reason ArQule Shares Rose as Much as 11% Today

2019-06-25 07:15:30 | The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

2019-06-25 07:00:00 | ArQule Announces Pricing of $90 Million Public Offering of Common Stock

2019-06-24 16:37:00 | ArQule Announces Commencement of Proposed Public Offering of Common Stock

2019-06-24 13:27:28 | Did Hedge Funds Drop The Ball On ArQule, Inc. ARQL ?

2019-06-18 16:01:00 | ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019

2019-06-18 07:31:03 | The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

2019-06-17 15:22:51 | Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal

2019-06-17 15:21:00 | ArQule Hits 12-Year High Following Favorable Midstage Study Results

2019-06-17 13:10:54 | 2 Rallying Pharma Stocks Roping In Option Bulls

2019-06-17 12:37:00 | Here's Why ArQule Is Soaring Again Today

2019-06-17 09:31:01 | Company News For Jun 17, 2019

2019-06-17 09:00:00 | ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib ARQ 092, in Patients with PIK3CA-related Overgrowth Spectrum PROS and Proteus syndrome PS in an Oral Presentation at the European Society of Human Genetics Conference

2019-06-15 12:38:28 | The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

2019-06-14 13:18:10 | ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results

2019-06-14 12:56:21 | A Look At Benzinga Pro's Most-Searched Tickers For June 14

2019-06-14 11:52:00 | Here's Why ArQule Shares Rose as Much as 44.7% Today